C57B1/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine
C57B1/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine
复制标题
DOI：
10.1016/j.vaccine.2007.01.037
复制
发表时间：
2007-04-20
期刊：
影响因子：
5.5
通讯作者：
Ward, Brian J.
中科院分区：
文献类型：
--
作者：
Cyr, Sonya L.;Jones, Taff;Ward, Brian J.
鼻内（IN）Protollin-eRSV疫苗的保护效力最近已在RSV易感BALB/c小鼠模型中得到证实。在此，我们报告Protollin-eRSV疫苗在相对耐药的C57 B1/6小鼠模型中的安全性、免疫原性和有效性。用两个或三个剂量的Protollin-eRSV IN免疫的C57 B1/6小鼠产生显著的全身和粘膜RSV特异性抗体。与仅接受抗原的动物相比，用Protollin疫苗免疫的小鼠在RSV再刺激的肺和脾细胞制剂中显示出极化的Th 1应答，其中IFN γ/IL-5比率增加。Protollin-eRSV免疫的C57 B1/6小鼠完全免受攻击，在用福尔马林灭活的RSV疫苗免疫的动物中没有观察到嗜酸性粒细胞肺病理学。这种新的模型将允许我们使用建立在C57 B1/6背景上的TLR敲除动物来剖析疫苗中所含的TLR 2和TLR 4配体的各自作用。(c)2007爱思唯尔有限公司保留所有权利。
The protective efficacy of an intranasal (IN) Protollin-eRSV vaccine has recently been demonstrated in the RSV-susceptible BALB/c mouse model. Here, we report the safety, immunogenicity and efficacy of Protollin-eRSV vaccine in the relatively resistant C57B1/6 mouse model. C57B1/6 mice immunized IN with either two or three doses of Protollin-eRSV produced significant systemic and mucosal RSV-specific antibodies. Mice immunized with the Protollin vaccine displayed polarized Th1 responses with augmented IFN gamma/IL-5 ratios in RSV-restimulated lung and spleen cell preparations compared with animals that received antigen alone. The Protollin-eRSV immunized C57B1/6 mice were fully protected against challenge without eosinophilic pulmonary pathology observed in the animals immunized with the formalin-inactivated RSV vaccine. This new model will permit us to dissect the respective roles of the TLR2 and TLR4 ligands contained in the vaccine using TLR knock-out animals established on the C57B1/6 background. (c) 2007 Elsevier Ltd. All rights reserved.